Company intelligence / Profile preview
Acrux Ltd
- Ownership
- Private
- Employees
- ~43
- Development stage
- Other
Overview
Acrux has successfully developed and commercialized multiple products including Dapsone 5% gel and 7.5% gel for acne vulgaris, Lidocaine and Prilocaine 2.5%/2.5% cream, and estradiol transdermal sprays (Lenzetto and Evamist) for menopause-related hot flushes[1][6][8]
- Therapeutic areas
- DermatologyGastroenterologyWomen's HealthInfectious Diseases
- Modalities
- Topical pharmaceuticalstransdermal delivery systems
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Acrux Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acrux Ltd.